Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm Female
Interventions: DRUG: Fulvestrant 500mg|DRUG: Palbociclib 125mg|DRUG: Goserelin 3.6 MG|DRUG: Placebos
Sponsor: International Cancer Research Group, United Arab Emirates
Collaborators: AstraZeneca|Pfizer|Genomic Health®, Inc.